Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers

被引：101

作者：

Duda, Dan G.

Jain, Rakesh K.

Willett, Christopher G.

机构：

[1] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA

[2] Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab Tumor Biol, Boston, MA 02114 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 26期

关键词：

D O I：

10.1200/JCO.2007.11.3985

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.

引用

收藏

页码：4033 / 4042

页数：10

相关论文

共 65 条

[21] Fractal characteristics of tumor vascular architecture during tumor growth and regression [J].

Gazit, Y ;

Baish, JW ;

Safabakhsh, N ;

Leunig, M ;

Baxter, LT ;

Jain, RK .

MICROCIRCULATION-LONDON, 1997, 4 (04) :395-402

[22] Effect of bevacizumab on radiation necrosis of the brain [J].

Gonzalez, Javier ;

Kumar, Ashok J. ;

Conrad, Charles A. ;

Levin, Victor A. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (02) :323-326

[23]

Gorski DH, 1999, CANCER RES, V59, P3374

[24] Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer [J].

Grothey, Axel .

SEMINARS IN ONCOLOGY, 2006, 33 (05) :S41-S49

[25] Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment [J].

Hobbs, SK ;

Monsky, WL ;

Yuan, F ;

Roberts, WG ;

Griffith, L ;

Torchilin, VP ;

Jain, RK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4607-4612

[26] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[27] Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts [J].

Inai, T ;

Mancuso, M ;

Hashizume, H ;

Baffert, F ;

Haskell, A ;

Baluk, P ;

Hu-Lowe, DD ;

Shalinsky, DR ;

Thurston, G ;

Yancopoulos, GD ;

McDonald, DM .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (01) :35-52

[28] Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab [J].

Ince, WL ;

Jubb, AM ;

Holden, SN ;

Holmgren, EB ;

Tobin, P ;

Sridhar, M ;

Hurwitz, HI ;

Kabbinavar, F ;

Novotny, WF ;

Hillan, KJ ;

Koeppen, H .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (13) :981-989

[29] Effect of vascular normalization, by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model [J].

Jain, Rakesh K. ;

Tong, Ricky T. ;

Munn, Lance L. .

CANCER RESEARCH, 2007, 67 (06) :2729-2735

[30] Molecular regulation of vessel maturation [J].

Jain, RK .

NATURE MEDICINE, 2003, 9 (06) :685-693

← 1 2 3 4 5 6 7 →